Pharma BD Deal Intelligence
Eisai's $205M cash purchase of Ligand's oncology portfolio bought a US commercial sales force but no durable assets—every acquired drug was later divested or withdrawn. It sold Targretin to Valeant in 2013 for $65M and pulled flagship ONTAK from the market in 2014 over manufacturing issues, leaving only an infrastructure assist to Halaven's later launch.
Eisai got its oncology sales force and CTCL foothold, but every acquired drug ended up divested, withdrawn, or marginal within a decade
Full analysis, sources & comparables →Eisai paid Ligand $205M cash for four oncology products (Ontak, Targretin capsules and gel, Panretin gel); Ligand framed the divestiture as part of refocusing…
Sales reshape Ligand as the company divests its oncology portfolio to Eisai and other product lines to refocus the business.
Eisai bought rights to Targretin and three other anti-cancer products from Ligand in 2006; the products served narrow CTCL and Kaposi's sarcoma indications and…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Acquired four oncology products: Ontak, Targretin (capsule and gel), Panretin
Eisai got its oncology sales force and CTCL foothold, but every acquired drug ended up divested, withdrawn, or marginal within a decade
Assessment window: 15yr post-close.
Cutaneous T-cell lymphoma is a rare non-Hodgkin lymphoma of skin-homing T cells, with mycosis fungoides and Sézary syndrome the dominant subtypes. AIDS-related Kaposi's sarcoma is a vascular tumor driven by HHV-8 in immunocompromised patients. Both are rare, treatment-refractory diseases where targeted topical/systemic agents play niche but important roles.
The four products Eisai acquired from Ligand for $205M each occupied narrow rare-disease niches. Ontak (denileukin diftitox), the first-ever FDA-approved fusion protein toxin (1999), targeted CD25+ persistent/recurrent CTCL but faced a small addressable population (CTCL incidence ~3,000-4,000 new U.S. cases/year). Targretin capsules and gel (bexarotene), an oral and topical retinoid X receptor agonist approved 1999-2000, served the same CTCL population, often used after methotrexate, interferon-alpha, or PUVA phototherapy. Panretin (alitretinoin gel) addressed AIDS-related Kaposi's sarcoma cutaneous lesions. Competing CTCL therapies of the era included Camptosar (off-label), Targretin itself, methotrexate, total skin electron beam therapy, and emerging HDAC inhibitors (vorinostat/Zolinza, approved 2006; later romidepsin/Istodax 2009). For Eisai, the deal was a U.S. oncology beachhead — building on its 2007 MGI Pharma ($3.9B) and Morphotek acquisitions to establish a hem/onc franchise. Ontak was voluntarily withdrawn in 2014 over manufacturing issues and later re-approved as Lymphir (denileukin diftitox-cxdl) in August 2024.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eisai Co., Ltd. / Ligand Pharmaceuticals (oncology product portfolio) (this deal) | 2006 | $205M | 41 |
| Eisai Co., Ltd. / MGI Pharma Inc. | 2007 | $3.9B | 36 |
| Eisai Co., Ltd. / Henlius | 2026 | — | — |
| Eisai Co., Ltd. / SEED Therapeutics Inc. | 2024 | $1.5B | — |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
← Browse all deals · How we score deals
More: 2006 deals · Eisai Co., Ltd. deals